Document is current
Any future updates will be listed below
-
Authors
Huang, Mei https://orcid.org/0000-0001-8671-3906
Wang, Dongyao https://orcid.org/0000-0003-1720-1135
Huang, Jiao https://orcid.org/0000-0002-6275-0451
Bae, An-Na https://orcid.org/0000-0002-2175-9679
Xia, Yun https://orcid.org/0000-0002-2818-1275
Zhao, Xutu https://orcid.org/0009-0003-0856-3481
Mortaja, Mahsa
Azin, Marjan https://orcid.org/0000-0001-6950-4854
Collier, Michael R.
Semenov, Yevgeniy R. https://orcid.org/0000-0002-7387-3094
Park, Jong Ho https://orcid.org/0000-0002-0488-7791
Demehri, Shadmehr https://orcid.org/0000-0002-7913-2641
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA283214)
Burroughs Wellcome Fund (CAMS)
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 6 June 2025
First Online: 27 June 2025
Competing interests
: J.H.P. and S.D. are coinventors on a filed patent for the use of IL-33 inhibition in the treatment of cancer, fibrosis, and inflammation (PCT/US21/40725). Other authors state no conflict of interest.
